Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease

Fibroblast growth factor 23 (FGF-23) is a phosphorus-regulating hormone. In chronic kidney disease (CKD), circulating FGF-23 levels are markedly elevated and independently associated with mortality. Left ventricular hypertrophy and coronary artery calcification are potent risk factors for mortality...

Full description

Saved in:

Bibliographic Details
Published in:	Circulation (New York, N.Y.) N.Y.), 2009-05, Vol.119 (19), p.2545-2552
Main Authors:	GUTIERREZ, Orlando M, JANUZZI, James L, WANG, Thomas J, DEFILIPPI, Christopher, WOLF, Myles, ISAKOVA, Tamara, LALIBERTE, Karen, SMITH, Kelsey, COLLERONE, Gina, SARWAR, Ammar, HOFFMANN, Udo, COGLIANESE, Erin, CHRISTENSON, Robert
Format:	Article
Language:	eng
Subjects:	Aged Biological and medical sciences Blood and lymphatic vessels Blood vessels and receptors C-Reactive Protein - analysis Calcinosis - blood Calcinosis - complications Cardiology. Vascular system Chronic Disease Comorbidity Coronary Occlusion - blood Coronary Occlusion - complications Coronary Occlusion - diagnostic imaging Cross-Sectional Studies Diabetes Mellitus - blood Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Female Fibroblast Growth Factors - blood Fundamental and applied biological sciences. Psychology Glomerular Filtration Rate Humans Hypertension - blood Hypertrophy, Left Ventricular - blood Hypertrophy, Left Ventricular - complications Hypertrophy, Left Ventricular - diagnostic imaging Hypertrophy, Left Ventricular - pathology Kidney Diseases - blood Kidney Diseases - complications Kidney Diseases - physiopathology Male Medical sciences Middle Aged Natriuretic Peptide, Brain - blood Obesity - blood Phosphates - blood Radiography Single-Blind Method Ultrasonography Vertebrates: cardiovascular system Vitamin D - blood
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Fibroblast growth factor 23 (FGF-23) is a phosphorus-regulating hormone. In chronic kidney disease (CKD), circulating FGF-23 levels are markedly elevated and independently associated with mortality. Left ventricular hypertrophy and coronary artery calcification are potent risk factors for mortality in CKD, and FGFs have been implicated in the pathogenesis of both myocardial hypertrophy and atherosclerosis. We conducted a cross-sectional study to test the hypothesis that elevated FGF-23 concentrations are associated with left ventricular hypertrophy and coronary artery calcification in patients with CKD. In this study, 162 subjects with CKD underwent echocardiograms and computed tomography scans to assess left ventricular mass index and coronary artery calcification; echocardiograms also were obtained in 58 subjects without CKD. In multivariable-adjusted regression analyses in the overall sample, increased log FGF-23 concentrations were independently associated with increased left ventricular mass index (5% increase per 1-SD increase in log FGF-23; P=0.01) and risk of left ventricular hypertrophy (odds ratio per 1-SD increase in log FGF-23, 2.1; 95% confidence interval, 1.03 to 4.2). These associations strengthened in analyses restricted to the CKD subjects (11% increase in left ventricular mass index per 1-SD increase in log FGF-23; P=0.01; odds ratio of left ventricular hypertrophy per 1-SD increase in log FGF-23, 2.3; 95% confidence interval, 1.2 to 4.2). Although the highest tertile of FGF-23 was associated with a 2.4-fold increased risk of coronary artery calcification > or =100 versus
ISSN:	0009-7322 1524-4539